Peter A Campochiaro1, Raafay Sophie2, Michael Tolentino3, Daniel M Miller4, David Browning5, David S Boyer6, Jeffrey S Heier7, Laura Gambino8, Barbara Withers8, Mitchell Brigell8, Kevin Peters8. 1. The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: pcampo@jhmi.edu. 2. The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Center for Retina and Macular Disease, Winter Haven, Florida. 4. Department of Ophthalmology, Cincinnati Eye Institute, University of Cincinnati School of Medicine, Cincinnati, Ohio. 5. Charlotte Eye, Ear, Nose & Throat Associates, Charlotte, North Carolina. 6. Retina Vitreous Associates Medical Group, Beverly Hills, California. 7. Ophthalmic Consultants of Boston, Boston, Massachusetts. 8. Aerpio Therapeutics, Cincinnati, Ohio.
Abstract
PURPOSE: AKB-9778 is a small-molecule competitive inhibitor of vascular endothelial-protein tyrosine phosphatase (VE-PTP) that promotes Tie2 activation and reduces vascular leakage and neovascularization in mouse models. The purpose of this study was to test the safety, tolerability, pharmacokinetics, and biological activity of AKB-9778 in patients with diabetic macular edema (DME). DESIGN: Open-label, dose-escalation clinical trial. PARTICIPANTS: Four dose cohorts of 6 patients with DME self-administered subcutaneous injections of 5 mg, 15 mg, 22.5 mg, or 30 mg AKB-9778 twice daily for 4 weeks. METHODS: Patients were seen weekly during a 4-week treatment period for safety assessments, best-corrected visual acuity (BCVA) assessment by Early Treatment Diabetic Retinopathy Study protocol, and measurement of central subfield thickness (CST) by spectral-domain optical coherence tomography. Additional safety assessments were performed at 6, 8, and 12 weeks. MAIN OUTCOME MEASURES: Safety assessments, change from baseline BCVA, and change from baseline CST. RESULTS: All doses were well tolerated. A modest, transient reduction in blood pressure and adverse events consistent with vasodilatory activity of AKB-9778 emerged at doses of 22.5 mg or more twice daily. At the week 4 primary end point, BCVA improved 5 letters or more from baseline in 13 of the 18 patients receiving 15 mg or more twice daily; 1 patient improved by 10 to 15 letters, and 2 patients improved by more than 15 letters. Among 18 patients receiving 15 mg or more twice daily, CST decreased by more than 100 μm in 5 patients and by 50 to 100 μm in 2 patients. There was a significant correlation between reduction in CST and improvement in BCVA. CONCLUSIONS: No safety concerns were identified after systemic administration of AKB-9778 for 4 weeks in patients with DME, and doses of 15 mg or more twice daily reduced macular edema and improved vision in some patients. This is a preliminary demonstration of clinical safety and efficacy of a VE-PTP inhibitor and Tie2 activator.
PURPOSE: AKB-9778 is a small-molecule competitive inhibitor of vascular endothelial-protein tyrosine phosphatase (VE-PTP) that promotes Tie2 activation and reduces vascular leakage and neovascularization in mouse models. The purpose of this study was to test the safety, tolerability, pharmacokinetics, and biological activity of AKB-9778 in patients with diabetic macular edema (DME). DESIGN: Open-label, dose-escalation clinical trial. PARTICIPANTS: Four dose cohorts of 6 patients with DME self-administered subcutaneous injections of 5 mg, 15 mg, 22.5 mg, or 30 mg AKB-9778 twice daily for 4 weeks. METHODS:Patients were seen weekly during a 4-week treatment period for safety assessments, best-corrected visual acuity (BCVA) assessment by Early Treatment Diabetic Retinopathy Study protocol, and measurement of central subfield thickness (CST) by spectral-domain optical coherence tomography. Additional safety assessments were performed at 6, 8, and 12 weeks. MAIN OUTCOME MEASURES: Safety assessments, change from baseline BCVA, and change from baseline CST. RESULTS: All doses were well tolerated. A modest, transient reduction in blood pressure and adverse events consistent with vasodilatory activity of AKB-9778 emerged at doses of 22.5 mg or more twice daily. At the week 4 primary end point, BCVA improved 5 letters or more from baseline in 13 of the 18 patients receiving 15 mg or more twice daily; 1 patient improved by 10 to 15 letters, and 2 patients improved by more than 15 letters. Among 18 patients receiving 15 mg or more twice daily, CST decreased by more than 100 μm in 5 patients and by 50 to 100 μm in 2 patients. There was a significant correlation between reduction in CST and improvement in BCVA. CONCLUSIONS: No safety concerns were identified after systemic administration of AKB-9778 for 4 weeks in patients with DME, and doses of 15 mg or more twice daily reduced macular edema and improved vision in some patients. This is a preliminary demonstration of clinical safety and efficacy of a VE-PTP inhibitor and Tie2 activator.
Authors: Daniel Dubinski; Elke Hattingen; Christian Senft; Volker Seifert; Kevin G Peters; Yvonne Reiss; Kavi Devraj; Karl H Plate Journal: J Cereb Blood Flow Metab Date: 2019-06-25 Impact factor: 6.200
Authors: Hannes C A Drexler; Matthias Vockel; Christian Polaschegg; Maike Frye; Kevin Peters; Dietmar Vestweber Journal: Mol Cell Proteomics Date: 2019-08-19 Impact factor: 5.911
Authors: Mingbing Zeng; Jikui Shen; Yuanyuan Liu; Lucy Yang Lu; Kun Ding; Seth D Fortmann; Mahmood Khan; Jiangxia Wang; Sean F Hackett; Gregg L Semenza; Peter A Campochiaro Journal: J Mol Med (Berl) Date: 2016-12-21 Impact factor: 4.599
Authors: Eric J Kim; Weijie V Lin; Sean M Rodriguez; Ariel Chen; Asad Loya; Christina Y Weng Journal: Curr Diab Rep Date: 2019-07-29 Impact factor: 4.810
Authors: Stefan H Oehlers; Mark R Cronan; Rebecca W Beerman; Matthew G Johnson; Jianhua Huang; Christopher D Kontos; Jason E Stout; David M Tobin Journal: J Infect Dis Date: 2017-03-01 Impact factor: 5.226
Authors: Peter A Campochiaro; Gulnar Hafiz; Tahreem A Mir; Adrienne W Scott; Ingrid Zimmer-Galler; Syed M Shah; Adam S Wenick; Christopher J Brady; Ian Han; Lingmin He; Roomasa Channa; David Poon; Catherine Meyerle; Mary Beth Aronow; Akrit Sodhi; James T Handa; Saleema Kherani; Yong Han; Raafay Sophie; Guohua Wang; Jiang Qian Journal: Am J Ophthalmol Date: 2016-04-27 Impact factor: 5.258